GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Viveve Medical Inc (OTCPK:VIVE) » Definitions » ROC %

Viveve Medical (Viveve Medical) ROC % : -216.16% (As of Sep. 2022)


View and export this data going back to 2016. Start your Free Trial

What is Viveve Medical ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Viveve Medical's annualized return on capital (ROC %) for the quarter that ended in Sep. 2022 was -216.16%.

As of today (2024-05-26), Viveve Medical's WACC % is 0.00%. Viveve Medical's ROC % is 0.00% (calculated using TTM income statement data). Viveve Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Viveve Medical ROC % Historical Data

The historical data trend for Viveve Medical's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viveve Medical ROC % Chart

Viveve Medical Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -689.63 -682.22 -381.58 -234.99 -370.49

Viveve Medical Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -408.18 -540.10 -323.13 -228.01 -216.16

Viveve Medical ROC % Calculation

Viveve Medical's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2021 is calculated as:

ROC % (A: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2020 ) + Invested Capital (A: Dec. 2021 ))/ count )
=-21.553 * ( 1 - 0% )/( (7.287 + 4.348)/ 2 )
=-21.553/5.8175
=-370.49 %

where

Viveve Medical's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2022 is calculated as:

ROC % (Q: Sep. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2022 ) + Invested Capital (Q: Sep. 2022 ))/ count )
=-18.648 * ( 1 - 0% )/( (8.411 + 8.843)/ 2 )
=-18.648/8.627
=-216.16 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Viveve Medical  (OTCPK:VIVE) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Viveve Medical's WACC % is 0.00%. Viveve Medical's ROC % is 0.00% (calculated using TTM income statement data). Viveve Medical earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Viveve Medical ROC % Related Terms

Thank you for viewing the detailed overview of Viveve Medical's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Viveve Medical (Viveve Medical) Business Description

Traded in Other Exchanges
N/A
Address
345 Inverness Drive South, Building B, Suite 250, Englewood, CO, USA, 80112
Viveve Medical Inc designs, develops, manufactures and markets a platform medical technology. Its Cryogen-cooled Monopolar Radiofrequency technology is delivered through a radiofrequency generator, handpiece and treatment tip, called the Viveve System. The Viveve System is for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The Viveve System is indicated for use and being marketed for use in general surgical procedures for electrocoagulation and hemostasis in the United States. It has a business presence in the US, Asia Pacific, Canada, Europe and Middle East and Latin America.
Executives
Presnell Sharon Collins director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Wilmot B. Harkey 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Daniel Mack 10 percent owner C/O NANTAHALA CAPITAL MANAGEMENT, LLC, 130 MAIN ST. 2ND FLOOR, NEW CANAAN CT 06840
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Karen L. Zaderej director AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Steven L Basta director 1875 S GRANT STREET SUITE 110, SAN MATEO CA 94402
Scott Durbin officer: Chief Financial Officer PO BOX 376, ANN ARBOR MI 48106
James G. Atkinson officer: CBO & President 150 COMMERCIAL STREET, SUNNYVALE CA 94086
Patricia Scheller director, officer: CEO and Director 150 COMMERCIAL STREET, SUNNYVALE CA 94086
Jon M Plexico director, 10 percent owner 16430 N SCOTTSDALE RD 450, SCOTTSDALE AZ 85254
Stonepine Capital Management, Llc director, 10 percent owner 919 NW BOND STREET, SUITE 204, BEND OR 97703
Timothy P Lynch director, 10 percent owner 919 NW BOND STREET, SUITE 204, BEND OR 97703
Daniel Janney director, 10 percent owner PO BOX 7414, JACKSON WY 83002